HC Wainwright Has Strong Forecast for KYMR FY2026 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share estimates for Kymera Therapeutics in a report released on Thursday, June 26th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($3.24) for the year, up from their prior estimate of ($3.35). HC Wainwright has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics' FY2027 earnings at ($3.53) EPS, FY2028 earnings at ($3.58) EPS and FY2029 earnings at ($3.23) EPS.

KYMR has been the subject of several other research reports. Oppenheimer lowered their price target on shares of Kymera Therapeutics from $56.00 to $53.00 and set an "outperform" rating for the company in a report on Friday. B. Riley raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $38.00 to $60.00 in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. boosted their target price on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 3rd. Morgan Stanley upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $49.00 to $79.00 in a research note on Tuesday, June 3rd. Finally, BTIG Research reaffirmed a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a report on Thursday. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $59.61.

Kymera Therapeutics Stock Performance

KYMR stock opened at $44.12 on Monday. The company's 50 day moving average price is $37.08 and its 200 day moving average price is $35.76. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -14.23 and a beta of 2.07. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same quarter last year, the company earned ($0.69) EPS. Kymera Therapeutics's revenue for the quarter was up 114.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock worth $276,395,000 after purchasing an additional 224,859 shares during the period. Wellington Management Group LLP increased its stake in Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock valued at $164,134,000 after buying an additional 689,547 shares during the period. Vanguard Group Inc. raised its position in Kymera Therapeutics by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after buying an additional 344,080 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after acquiring an additional 650,000 shares during the period. Finally, Siren L.L.C. lifted its stake in shares of Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after acquiring an additional 270,580 shares during the period.

Insider Activity

In related news, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer now directly owns 660,482 shares of the company's stock, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,349 shares of company stock valued at $2,334,301. 16.01% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.